However, the activated conformation of the CysLT2R receptor upon binding to an endogenous ligand remains elusive. The precise molecular details of "ligand–receptor" coupling cannot be elucidated ...

Ligand Pharmaceuticals Incorporated ... a dual endothelin and angiotensin II receptor antagonist for immunoglobulin A nephropathy; Ohtuvayre for respiratory disease; PNEUMOSIL, a pneumococcal ...

Ligand and investors are contributing $50 million to support the Pelthos-Channel merger, set to close summer 2025. FDA-approved Zelsuvmi is the first at-home prescription for molluscum, a skin ...

Stifel starts Ligand coverage with Buy rating, $43 target; cites strong royalty-financing model and biotech partnerships. Ligand posts 20%+ revenue and 35%+ EPS growth since 2022 restructure ...

Ligand Pharmaceuticals’ topical skin infection gel Zelsuvmi is changing hands again—sort of. After Ligand last year created Pelthos Therapeutics to support the launch of Zelsuvmi, Pelthos is ...

(RTTNews) - Ligand Pharmaceuticals Inc. (LGND) Thursday announced a definitive merger agreement with Channel Therapeutics Corp.(CHRO) to combine Ligand's wholly owned subsidiaries, Pelthos ...

Receptor performance was assessed based on on ... the study opted for a modular approach, modeling ECD–ligand complexes ...

JUPITER, Fla., March 03, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo ...